Renal Cell Carcinoma More Advanced at Presentation in Younger Patients Than Those 21-30 Years Old
the Cancer Therapy Advisor take:
According to a study published online in The Journal of Urology, researchers have found that children and adolescents with renal cell carcinoma present with more advanced disease than those aged 21 to 30 years with renal cell carcinoma.
For the study, researchers sought to identify differences in renal cell carcinoma presentation and outcomes of children, adolescents, and young adults with the disease. They identified 3,658 patients less than 30 years of age who were diagnosed with chromophobe, clear cell, papillary, and renal cell carcinoma NOS (unclassified) between 1998 and 2011 from the National Cancer Database.
They also found that younger patients were more likely to present with higher staged disease (P < 0.0001), higher grade disease (P < 0.0001), and bigger tumors (P < 0.0001). Furthermore, younger patients were more likely than patients aged 21 to 30 to undergo lymph node resection (P < 0.0001) and receive chemotherapy as first-line therapy for the disease.
The researchers also identified various risk factors associated with mortality in patients under 21 years of age with renal cell carcinoma, including stage 4 at diagnosis, government insurance status, non-chromophobic pathology, and not opting for surgery as first-line therapy for the disease.
Children and adolescents with renal cell carcinoma present with more advanced disease.
Children and adolescents with RCC present with more advanced disease than those 21–30 years old. In patients <21, mortality was associated with the non–chromophobe histological subtype, stage 4 disease, government insurance, and not undergoing surgery as first line therapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer